MEMORY PHARMA AMENDS DEAL WITH ROCHE
Biopharmaceutical company Memory Pharmaceuticals Corp. said Friday that Swiss drug maker Roche Holding AG has reconsidered its development of two possible Alzheimer's disease treatments it licensed under a 2002 agreement. Montvale, N.J.-based Memory said Roche will reacquire the right to develop and commercialize two PDE4 inhibitors called MEM 1414 and MEM 1917. PDE4 is a type of enzyme that is believed to regulate mood. Roche halted development of the compounds in April, pending further discussions between the two companies.
Crain's New York Business (http://www.newyorkbusiness.com/news.cms?id=11483)